George Goldsmith Talks About His Drug for Treating Depression

Compass Pathways developed a synthetic form of psilocybin, the psychoactive ingredient found in “magic mushrooms,” for use in treating depression. CEO George Goldsmith says the key is using the hallucinogenic as part of a broader therapy.

● Goldsmith and his physician wife were drawn to research on hallucinogenic mushrooms while seeking a treatment for their son’s mental health issues. ● The Food and Drug Administration designated their work a “breakthrough therapy” in 2018 ● It’s now in Phase II trials